Project description:<p><em>Ulmus parvifolia</em> (<em>U. parvifolia</em>) was traditionally used in the treatment of some diseases such as inflammation, diarrhea and fevers. With the wide application of molecular biotechnology in plant development and utilization, the pharmaceutical value and chemical composition of the bark and leaves of <em>U. parvifolia</em> had been studied. However, metabolic signatures of seeds have not been studied. Seeds and bark of <em>U. parvifolia</em> were collected at the seeds ripening stage and metabolite profiling was performed through the untargeted metabolomics approach. A total of 2,578 and 2,207 metabolites were identified in seeds and bark, respectively. In particular, 574 differential metabolites were identified from the two parts of <em>U. parvifolia</em>, including flavonoids, terpene glycosides, triterpenoids and sesquiterpenoids. There are some bioactive compounds with antioxidant, anti-inflammatory and anti-cancer activities in these metabolites. More metabolites belonged to flavonoids and sesquiterpenoids were up-regulated in seeds than that in bark. There were more varieties of terpene glycosides and triterpenoids in bark than seeds. The pathway enrichment was performed, while flavonoid biosynthesis and flavone and flavonol biosynthesis were worthy of attention. Metabolic signatures of <em>U. parvifolia</em> seeds and bark were analyzed by untargeted metabolomics approach. Metabolite profiling, characteristics of differential metabolites and pathway enrichment were performed to evaluate the pharmaceutical value of seeds and bark. This study provided a scientific basis for the complementary use of the two different parts of <em>U. parvifolia</em> as a Chinese medicinal material.</p>
2024-01-09 | MTBLS4572 | MetaboLights
Project description:Plastome and phylogenetic relationship of Torreya parvifolia
Project description:Nanopore Sequencing and assembly of Col-0 carrying seed coat expressed GFP and RFP transgenes flanking the centromere of chromosome 3 (CTL 3.9) - additionally, DNA methylation was derived using deepsignal-plant using these reads.
Project description:Using RNA sequencing and de novo transcript assembly, we identified 4516 lncRNAs expressed in 8 different stages of B cell development and activation. Chromatin immuno-precipitation sequencing was used to classify a substantial fraction (38%) of these lncRNAs as enhancer-associated or promoter-associated RNAs (eRNAs or pRNAs). A catalogue of lncRNAs expressed in eight murine B cell populations
Project description:Due to the large size, complex splicing and wide dynamic range of eukaryotic transcriptomes, RNA sequencing samples the majority of expressed genes infrequently, resulting in sparse sequencing coverage that can hinder robust isoform assembly and quantification. Targeted RNA sequencing addresses this challenge by using oligonucleotide probes to capture selected genes or regions of interest for focused sequencing. This enhanced sequencing coverage confers sensitive gene discovery, robust transcript assembly and accurate gene quantification. Here we describe a detailed protocol for all stages of targeted RNA sequencing, from initial probe design considerations, capture of targeted genes, to final assembly and quantification of captured transcripts. Initial probe design and final analysis can take less than a day, while the central experimental capture stage requires ~7 days.
Project description:This dataset contains Xdrop followed by oxford nanopore long read sequencing performed in target tRNA gene deletion clones in HAP1 (t72) and HepG2 (t15). By applying de novo assembly based approach to Xdrop-LRS data, we identified Cas9-induced on-target genomic alteration.
